Table 1 Baseline characteristics of patients initiated on olanzapine, risperidone, and quetiapine
Variable | Olanzapine N = 405 | Quetiapine N = 115 | Risperidone N = 276 |
|---|---|---|---|
Age, mean (S.D.) | 41.8 (10.5) | 39.6 (10.9) | 40.4 (12.1) |
Illness duration (yrs), mean (S.D.) * a,b | 22.1 (11.3) | 18.5 (11.2) | 19.9 (12.4) |
Male gender* b | 61.7% | 47.8% | 54.7% |
Ethnicity | |||
White | 46.7% | 53.9% | 45.3% |
Black | 41.2% | 33.9% | 36.6% |
Other | 12.1% | 12.2% | 18.1% |
Schizoaffective disorder | 32.6% | 40.0% | 33.3% |
Substance-use disorder* b,c | 30.9% | 19.3% | 29.4% |
No insurance | 6.9% | 8.9% | 9.2% |
Polypharmacy at initiation * a,c | 67.2% | 76.5% | 59.8% |
Prior treatment pattern † | |||
Prior Antipsychotic monotherapy days, mean (S.D.)* a | 42.4 (26.0) | 39.2 (27.7) | 36.8 (28.0) |
Prior psychiatric hospitalization* a | 21.0% | 21.7% | 29.4% |
Prior atypical antipsychotic* b,c | 23.5% | 69.6% | 28.6% |
Prior typical oral antipsychotic* b,c | 63.5% | 39.1% | 58.7% |
Prior typical depot antipsychotic* a,b | 23.2% | 13.9% | 15.9% |
Prior antidepressants | 35.6% | 45.2% | 40.9% |
Prior anti-anxiety agents | 10.4% | 14.8% | 12.0% |
Prior antiparkinsonians agents | 46.9% | 36.5% | 47.5% |
Prior mood stabilizers* a,c | 30.1% | 39.1% | 23.2% |
Prior sleep agents | 0.7% | 3.5% | 2.2% |